After temporarily halting the IPO in May due to US-China tensions, Douyu has relaunched its efforts with a target of $944m in proceeds and moved its proposed listing from NYSE to Nasdaq.

IndiaMart, backed by Intel Capital and Brand Equity Treaty, has listed on the National Stock Exchange after raising $69m in its initial public offering.

Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.

The co-working space service is aiming to raise up to $200m in an initial public offering in the US next year, with multiple real estate developers in line for exits.

PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.

Codiak Biosciences has withdrawn its proposed offering citing unfavourable market conditions, delaying an exit for investors including Alexandria Real Estate Equities.

Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.

The corporate-backed small molecule therapeutic developer has boosted its initial public offering from $90m to nearly $104m.

Health management app developer Livongo Health was valued at $800m as of 2018, and a range of corporate investors could exit in the offering.

UPMC and Kaiser Permanente are both in line for exits after health data platform developer Health Catalyst filed for a $100m initial public offering.